Charles River Laboratories 2026: Revenue $982.73M, EPS $6.86— 10-Q Summary
Charles River Laboratories reported Q3 2026 revenue of $982.73M, down 2.2% YoY, while net income rose to $333.07M and EPS increased to $6.86. Management cited improving demand in Discovery and Safety Assessment, portfolio changes, and cost savings. Nine-month revenue declined 1.3%, with growth in microbial testing and China model sales. The company completed divestitures and acquisitions, targeting $300M in annual savings by 2026.
How this was made
The 30-second read
Why it matters
The earnings release offers fresh data for traders to reassess valuation, especially given the mixed revenue and earnings signals.
Market read
Primary earnings news for a mid‑cap biotech services firm; relevant for sector‑focused investors.
What to watch
Divestitures and new acquisitions (PathoQuest, Cambodian supplier) may drive future growth not reflected in the current quarter.
Background
The article summarizes the company's 10‑Q filing, providing key financial metrics and strategic moves.
Ticker impact
Charles River Laboratories reported Q4 2026 results with revenue down 2.2% to $982.73M and EPS up to $6.86, a primary earnings disclosure.
potential modest downside as revenue decline may pressure the stock, though profit growth could limit the drop
Revenue contraction suggests weaker demand, while EPS beat signals cost control; market likely weighs both factors.
Market effects
Highlights pressure on the contract research services sector as biotech funding moderates.
US biotech and pharma service providers may see short-term valuation adjustments.
Limited to life‑science services; no broad market impact.
Counterpoint
Despite revenue decline, the strong EPS beat and cost‑saving initiatives could support upside if investors focus on profitability.
Key entities
- companyCharles River Laboratories International
Provider of preclinical and clinical laboratory services.
